ZYDELIG
PeakNDAORALTABLET
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYDELIG (idelalisib) is an oral small-molecule kinase inhibitor approved in 2014 for hematologic malignancies, specifically targeting PI3K delta in B-cell cancers. It works by inhibiting phosphatidylinositol 3-kinase (PI3K) delta, a key signaling enzyme in malignant B cells. The drug is indicated for chronic lymphocytic leukemia, follicular lymphoma, and small lymphocytic lymphoma, typically in combination with other agents.
Peak6.8 years to LOE
Peak-stage product with established market presence; commercial teams focus on physician relationships and competitive differentiation against JAK and multi-kinase inhibitor alternatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Started Oct 2017
17 enrolled
Non Hodgkin LymphomaFollicular LymphomaIndolent Lymphoma+6 more
Career Relevance
ZYDELIG careers center on defending peak-stage market share against kinase inhibitor competition and preparing for 2033 LOE transition. Roles emphasize physician engagement, payer negotiations, and lifecycle extension strategies rather than launch activities.
Brand Manager
Worked on ZYDELIG at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.